BioSpace News Archive

This new patent covers conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology AccumTM.

The Cancer Tumor Profiling Market is expected to reach USD 31.99 Billion by 2027, according to a new report by Emergen Research.

According to the current analysis of Emergen research, the global Follicular lymphoma treatment market was valued at USD 2.08 billion in 2019 and is expected to reach USD 3.73 billion by 2027, at a CAGR of 7.6%.

The global In-Vitro Diagnostics (IVD) market size is expected to reach USD 118.44 Billion at a steady revenue CAGR of 4.4% in 2028, according to latest analysis by Emergen Research.

Vaccinex, Inc. (Nasdaq: VCNX), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research.

Wilmington, Delaware, United States, Transparency Market Research Inc. – According to Transparency Market Research’s latest report on the global transcatheter embolization and occlusion devices market for the historical period 2017–2018 and forecast period 2019–2027.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global optometry equipment market is generating credible opportunities, as global eye care makes impressive strides.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The global non-alcoholic steatohepatitis biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a rapid pace from 2019 to 2027.

Helsinn Group announces its participation in the upcoming IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, taking place from 6-9 August in Vienna, Austria.

HUTCHMED and AstraZeneca announce that preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® plus savolitinib demonstrated an objective response rate of 49% in patients with epidermal growth factor receptor-mutated non-small cell lung cancer with high levels of mesenchymal epithelial transition overexpression and/or amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on treatment with TAGRISSO®.